Novozymes downgrades following failing sales
![Photo: Novozymes/PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article4651913.ece/ALTERNATES/schema-16_9/nzflagbig.jpg)
Novozymes' US sales have not panned out, limiting the Danish enzyme producer's growth.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novozymes' US growth outlook dwindles
For subscribers
Novozymes CFO: Powerful momentum in bioenergy division
For subscribers
Novozymes' bioenergy division continues to grow
For subscribers